FilingReader Intelligence
Huadong Medicine subsidiary secures exclusive rights for JAK1 inhibitor
August 11, 2025 at 05:14 PM UTC•By FilingReader AI
Huadong Medicine's wholly-owned subsidiary secured exclusive commercialization rights for VC005, a novel oral JAK1 inhibitor, in mainland China.
The company will pay 50 million yuan upfront plus up to 180 million yuan in registration milestones. VC005 is in Phase III trials for atopic dermatitis and Phase II for ankylosing spondylitis.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000963•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Huadong Medicine publishes news
Free account required • Unsubscribe anytime